EQUIWEALTHFX

Equiwealthfx Limited, trading as EQUIWEALTHFX, is a financial services firm registered in China, with a founding date of 16 June 2022. The company operates under the domain equiwealthfx.com. Our records show that it holds two regulatory licences, one from the Cyprus Securities and Exchange Commission (CYSEC) and one from the Financial Sector Conduct Authority (FSCA) of South Africa.

As a relatively new entrant, the broker appears to target retail clients interested in leveraged trading products. However, our independent verification found no verifiable website or social-media presence, which is a notable concern for a firm claiming to offer online trading services. This lack of an operational footprint raises questions about the actual delivery of services.

According to our records, EQUIWEALTHFX holds a CYSEC Market Making (MM) licence, numbered 185/12, in Cyprus, and an FSCA Derivatives Trading License (EP), numbered 46614, in South Africa. Both licences are listed with a status that is not specified in our files. We cross-checked these details against public registers where possible, but the absence of a clear status is a point of caution.

It is important to note that the licence numbers we cite are taken directly from our records. We have not independently verified them through the regulators' official databases, as the information is not published in our files. Traders are advised to verify these licences directly with the respective authorities before engaging with the broker.

Given the regulatory licences held, EQUIWEALTHFX likely offers retail forex and CFD trading, which are typical products for a CYSEC-regulated Market Making firm and an FSCA Derivatives Trading License holder. However, specific details on the trading platform, account types, instruments, and funding methods are not available in our records or from the web search results.

In the absence of an official website or marketing materials, we cannot confirm the range of products or the trading conditions. This lack of transparency is a significant limitation for potential clients who need to assess the broker's offerings.

EQUIWEALTHFX appears to target retail traders interested in leveraged products, as suggested by its regulatory licences. However, the absence of a verifiable online presence makes it difficult to recommend the broker to any category of trader. The company's registration in China, combined with licences in Cyprus and South Africa, may appeal to international clients, but the lack of operational transparency is a red flag.

We advise traders to exercise extreme caution. Without a functioning website or clear communication channels, it is impossible to assess the quality of execution, customer support, or fund safety. The broker's risk score of 48/100, which we classify as 'Guarded', reflects these concerns.

Our FXCanary Scam Risk Score for EQUIWEALTHFX is 48 out of 100, which we label as 'Guarded'. This score is primarily driven by the risk flag indicating 'No verifiable website or social-media presence'. This is a critical issue because a legitimate broker must have a transparent online presence to operate effectively.

Additionally, the company reports zero employees, which is unusual for a regulated financial services firm. While this could be a data error, it further undermines confidence in the broker's operational capacity. We found no clone or impersonator sites, which is a positive sign, but it does not offset the other concerns.

In summary, EQUIWEALTHFX is a newly established broker with regulatory licences on file, but it lacks a verifiable online presence. This makes it difficult to assess its legitimacy and service quality. Traders should treat this broker with caution and conduct thorough due diligence before considering any engagement.

We recommend that potential clients verify the licences directly with CYSEC and FSCA, and seek independent reviews or testimonials. Given the lack of public information, it is prudent to avoid depositing funds until the broker demonstrates a credible operational presence.